Great Valley Advisor Group, Inc. Summit Therapeutics Inc. Transaction History
Great Valley Advisor Group, Inc.
- $4.07 Billion
- Q4 2024
A detailed history of Great Valley Advisor Group, Inc. transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Great Valley Advisor Group, Inc. holds 25,101 shares of SMMT stock, worth $456,336. This represents 0.01% of its overall portfolio holdings.
Number of Shares
25,101
Previous 25,000
0.4%
Holding current value
$456,336
Previous $547,000
18.1%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$444 Million4.83% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.7MShares$212 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$119 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$102 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.66B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...